Le Lézard
Classified in: Health, Science and technology, Business
Subjects: ERN, CCA

Tobii AB Interim Report Q2 2018


STOCKHOLM, July 20, 2018 /PRNewswire/ --  Tobii AB today reported its results for the first quarter and first six months 2018.

Comment by Tobii's CEO Henrik Eskilsson:

"All three business units developed well in the second quarter. Tobii Dynavox more than doubled the number of units sold compared with the same period the previous year, Tobii Pro delivered yet another very strong quarter in terms of sales, and Tobii Tech advanced in both VR and PC gaming."

Second quarter April?June 2018

Significant events

Conference call

Today at 2:00 p.m. CET, Tobii will host a conference call with web cast presentation for media, analyst and investors. Please find dial-in details on Tobii's website under Interim Report Q2 2018.

This information is information that Tobii AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, on July 20, 2018, at 8:00 a.m. CET.

Contact:

Sara Hyléen,
Director of Corporate Communications & Investor Relations,
Tobii AB,
phone: +46-709-16-16-41,
email: [email protected]

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/tobii-ab/r/tobii-ab-interim-report-q2-2018,c2578718

The following files are available for download:

http://mb.cision.com/Main/2874/2578718/881054.pdf

Tobii AB Interim Report Q2 2018 - 20 JULY 2018

http://mb.cision.com/Public/2874/2578718/bcdd190c4a32f8ea.pdf

Tobii AB interim Report Q2 2018 - Press Release - 20 July 2018

 


These press releases may also interest you

at 07:10
Science Corporation ("Science"), a leader in brain-computer interface ("BCI") technology and the developer of the Science Eye, has acquired the IP and related assets for the PRIMA retinal implant, developed by Pixium Vision SA ("Pixium") of France, a...

at 07:05
GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you...

at 07:05
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first...

at 07:05
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study...

at 07:05
Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today announced the launch of a new single-cell capability that enhances our understanding of translocations (chromosomal rearrangements) in gene-edited therapies....

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the...



News published on and distributed by: